About the Center
The Diabetes and Endocrinology Center of Western New York is part of a comprehensive clinical care and education program sponsored by the State University of New York at Buffalo School of Medicine is lead by Paresh Dandona M.D., who has had an illustrious career in both American and English Medicine.
After contributing more than 400 publications for medical literature, Dr. Dandona continues to make research a high priority. The center currently has several studies in progress and more are in the process of being realized in the future.
The Diabetes and Endocrinology Center of WNY is actively recruiting patients for different research studies in the field of diabetes, obesity and endocrine diseases. Please visit our research page for a list of active research studies available.
Our clinical unit offers the best care possible for Diabetes, which is considered to be the most expensive chronic disease in the United States, as well as for other endocrine pathologies. The center is due to see 16,000 patients this year, making it the biggest academic diabetic unit in New York state.
Director Paresh Dandona, MD
SUNY Distinguished Professor
Precision in Science, Just as in Nature
Our director, Dr. Dandona’s pioneering work in the diabetic center lead to his appointment as an advisor to Independent Health, Blue Cross, Blue Shield and to Community Blue in matters related to diabetes. We’ve authored algorithms in diabetic management, which we disseminated to primary care physicians so that care of diabetes can be improved and it’s complications prevented.
Various community programs have been set up by the Center for the city, which include: Public health surveys which screens for hypercholesterolemia, diabetes, hypothyroidism and hypertension starting in 1995 and then annually thereafter. Data from initial surveys have shown us for the first time that 2/3 of Buffalo’s population has hypercholesterolemia (high cholesterol) and that the prevalence of diabetes in the region is eight percent. So far 9500 Western New Yorkers have been surveyed. Every year we do our best to raise funds for this activity which amounts to $45,000-50,000. These screenings are done in association with the Erie County Health Dept.
A unique Diabetes Patients’ Forum which meets every two months, since October 1996, which aims to empower and educate diabetic patients and their families. This forum aims to educate patients and their families regarding their conditions and empower them to ask questions regarding the management of their disease.
Endocrinology Diary for 2013
Dr. Dandona participated in global consultants meeting related to the new anti-diabetic drug, TAK-875, from Takeda Pharmaceuticals in London, UK. This new class of drugs binds to a fatty acid receptor on the β-cell in the pancreatic islet and induces the release of insulin. The fall in HbA1c is just under 1% and there is no risk of hypoglycemia. Dr Prabhakar Viswanathan, Senior Medical Director in Takeda, is leading the program to develop this drug. Dr Viswanathan is an ex-fellow from our research program from UB. He is the third fellow trained by Dr Dandona to hold such a senior position in a major pharmaceutical company. Drs Davinder (Dave) Gill and Jaswinder (Jaz) Gill (Sanofi-Aventis) are the other two.
Department of Medicine Research Day
Immunometabolism Symposium, Toronto
ADA meeting: Chicago IL
Abstracts on Research
Endocrine Society, San Francisco
Abstracts Presented with oral presentation
Our paper on effects of liraglutide in obese patients with type 1 diabetes is published online in Endocrine Practice.
Webmaster contact: firstname.lastname@example.org
|Division of Endocrinology, Diabetes, and Metabolism,
State University of New York at Buffalo